89bio
89bio
ETNB
NASDAQ
7.80
USD
-4.65%
About
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 427.6K |
| Three Month Average Volume | 19.1M |
| High Low | |
| Fifty-Two Week High | 18.2499 USD |
| Fifty-Two Week Low | 6.575 USD |
| Fifty-Two Week High Date | 05 Sep 2023 |
| Fifty-Two Week Low Date | 23 Oct 2023 |
| Price and Volume | |
| Current Price | 9.5 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 0.92% |
| Thirteen Week Relative Price Change | 12.36% |
| Twenty-Six Week Relative Price Change | -31.54% |
| Fifty-Two Week Relative Price Change | -55.77% |
| Year-to-Date Relative Price Change | -28.18% |
| Price Change | |
| One Day Price Change | 2.93% |
| Thirteen Week Price Change | 20.25% |
| Twenty-Six Week Price Change | -24.72% |
| Five Day Price Change | 7.28% |
| Fifty-Two Week Price Change | -44.57% |
| Year-to-Date Price Change | -14.95% |
| Month-to-Date Price Change | 3.71% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 5.75008 USD |
| Book Value Per Share (Most Recent Quarter) | 4.90794 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 5.75008 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 4.90794 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.16789 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.9978 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.97256 USD |
| Normalized (Last Fiscal Year) | -1.98684 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.9978 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.97256 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.9978 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.97256 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.20643 USD |
| Cash Per Share (Most Recent Quarter) | 5.06489 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.9971 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.9791 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.8768 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 58.13% |
| Tangible Book Value (5 Year) | 138.05% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -36.58% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 7.22% |
| EPS Change (Trailing Twelve Months) | 6.52% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -506,259,000 |
| Net Debt (Last Fiscal Year) | -554,075,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 5 |
| Long Term Debt to Equity (Most Recent Quarter) | 4 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 20 |
| Current Ratio (Most Recent Quarter) | 14 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -129,190,000 |
| Free Cash Flow (Trailing Twelve Months) | -165,542,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 5 |
| Total Debt to Equity (Most Recent Quarter) | 5 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -35.86% |
| Return on Assets (Trailing Twelve Months) | -32.50% |
| Return on Assets (5 Year) | -45.50% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -41.33% |
| Return on Equity (Trailing Twelve Months) | -36.50% |
| Return on Equity (5 Year) | -53.11% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -38.49% |
| Return on Investment (Trailing Twelve Months) | -34.68% |
| Return on Investment (5 Year) | -49.31% |